Silihan lan utang jangka dawa perusahaan: Fractyl (GUTS)

Fractyl Health, Inc. (GUTS) restores natural metabolism by eliminating the root causes of diabetes through tissue regeneration. This US developer leverages advanced obesity treatment methods and support from specialized investors. Current price action on GURU.Markets is 0.00, while the business focuses on identifying strategic partners for the subsequent licensing of its platform following the completion of clinical trials.

GUTS Utang jangka dawa perusahaan Fractyl Health, Inc. (21.02.2024 - 30.10.2026)

Ringkesan rincian data analitis Fractyl (GUTS)

- rega pasar lan target rega analis:

Rega saham fractyl.com|GUTS - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Nilai pasar Fractyl Health|GUTS - Nilai Total Perusahaan

- informasi kapitalisasi buku:

Nilai Akuntansi saben Saham Fractyl Health|GUTS - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku fractyl.com|GUTS - Gunggung Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Rasio Kabeh Utang marang Dana Pribadi Fractyl Health, Inc.|GUTS - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Fractyl Health, Inc|GUTS - Gunggung utang perusahaan|Utang-utang marang nilai buku Fractyl Health|GUTS - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Fractyl Health|Rasio cepet fractyl.com

- data bathi lan kelipatan valuasi:

GUTS - Bathi resik

Ringkesan analitik perusahaan:Fractyl Health, Inc.

The 0.00 metric is formed by aggregating all liabilities with a maturity of more than one year, reflecting the business's dependence on external financing. Amid competition from GLP-1 drugs and clinical trial risks, analyzing the long-term debt of Fractyl Health, Inc. (GUTS) allows for an assessment of the company's financial resilience to develop invasive diabetes treatments without critical pressure from creditors.

Analisis pesaing Fractyl Health, Inc.